itrates are commonly used in patients with coronary artery disease because they relax vascular smooth muscle and the vasodilator effects are evident in systemic arteries including coronary vessels. 1 These effects are also evident in systemic veins and the venodilator effect
diac events in patients with severe AMI on long-term and continuous use of long-acting nitrates compared with those without nitrate administration. However, the overall randomization rate was rather low and data were not adjusted for patient background in either of these studies. Nagao et al indicated that there was no significant difference in the incidence of cardiac events within 5 years after AMI in patients on long-term nitrate administration than in those without, after adjustment for age. 9 In Japan, emergency percutaneous coronary intervention (PCI) is currently performed in approximately 80% of patients in the acute phase of MI and successful coronary reperfusion of the culprit lesion is reported in approximately 90%. [10] [11] [12] There is no clinical evidence that long-term nitrate treatment has any clinical benefit in patients undergoing PCI for AMI.
The present study was designed to determine the effects of long-term nitrate therapy on adverse events in patients with AMI in the coronary interventional era.
Methods

Data Sources
The Japanese Acute Coronary Syndrome Study (JACSS) is a retrospective and multicenter observational study conducted at 35 medical institutions in Japan. The JACSS database includes 1,236 consecutive patients hospitalized at the participating institutions within 48 h of the onset of symptoms of AMI from January to December 2003. AMI was defined as elevated myocardial enzyme concentrations, with either typical chest pain persisting longer than 30 min or ECG changes (including ischemic ST-segment depression, ST-segment elevation, or pathologic Q waves). Elevated enzyme concentrations were defined as peak creatine kinase (CK) levels more than twice the normal upper limit. The study protocol was reviewed and approved by the ethical committee of each participating institution.
Patients and Nitrate Prescription
After hospital admission, nitrates were administered according to the priority of the attending physician. The 1,236 patients were divided into a nitrate group consisting of 312 patients who continuously received long-acting nitrates (long-acting oral isosorbide mononitrate, long-acting oral isosorbide dinitrate, long-acting transdermal nitroglycerin, or long-acting transdermal isosorbide dinitrate) and a control group consisting of 924 patients who were not prescribed long-acting nitrates during hospitalization and never received them after discharge. The clinical data were obtained from the medical records of in-and outpatients of each hospital. Patients who were treated with antihypertensive drugs or those whose baseline blood pressure was ≥140/90 mmHg were considered hypertensive. Diabetes mellitus was diagnosed according to the criteria of the World Health Organization. 13 Hyperlipidemia was defined as total cholesterol ≥220 mg/dl and/or triglyceride ≥150 mg/dl. Cigarette smoking was defined as active smoking.
Coronary Angiography and Reperfusion Therapy
The allocation of coronary angiography and reperfusion therapy were determined by the physician. 
Mortality and Cardiovascular Events
The primary endpoint was mortality from any cause. Cardiac events (cardiac death, non-fatal reinfarction, unstable angina and heart failure requiring emergency rehospitalization) and cardiovascular events (stroke in addition to cardiac events) were also assessed. We evaluated the 30-day, 60-day, 90-day, 6-month, 1-year, and 2-year adverse event rates following AMI.
Statistical Analysis
Univariate comparisons of clinical characteristics were carried out between the nitrate group and the control group using chi-square test for dichotomous variables and unpaired t-test for continuous variables. Clinical characteristics considered to be associated with nitrate administration included age, sex, background illness (hypertension, diabetes mellitus, hyperlipidemia), smoking, serum creatinine levels, ST-elevation and Q-wave MI on electrocardiographic fingings, admission characteristics (body mass index (BMI), previous MI, preinfarction angina pectoris), time from symptom onset, coronary angiographic findings (multivessel involvement, culprit location), peak CK levels and medications during hospitalization and after discharge. Killip classes on hospital admission, depending on the clinical manifestations of cardiac failure, were also assessed (Killip I, no heart failure; Killip II, S3 and/or basal lung crepitations; Killip III, acute pulmonary edema; Killip IV, cardiac shock). 15 The incidences of all-cause mortality, cardiac events, and cardiovascular events were calculated by dividing the number of events by the number of cases followed-up for the 2 groups. We tested differences between the curves of the 2 groups for statistical significance by the log-rank analysis.
In an additional effort to balance the patient groups, we used propensity score analysis to generate a set of matched cases (patients with nitrate administration) and controls (patients without nitrate administration). The propensity score was calculated for each patient based on a logistic regression analysis of the probability of nitrate prescription using clinical characteristics. With these propensity scores, we then used a greedy matching technique to create a 1-to-1 match of cases with controls as described by Parsons. 16 Comparisons between the 2 matched groups based on clinical characteristics were carried out using chi-square test and unpaired t-test to confirm that the groups had been successfully matched. We calculated again the incidences of all-cause mortality, cardiac events, and cardiovascular events and compared the 2 matched groups.
All analyses were performed using the SAS software package version 9.1 (SAS, Cary, NC, USA).
Results
Clinical Background
The characteristics of the patients with and without longterm nitrate administration after AMI are listed in Table 1 . Of the 1,236 patients included in the study, 981 (78%) underwent emergency PCI and 911 (93%) of them achieved successful coronary reperfusion (TIMI grade 3 flow). Patients were followed-up for a mean period of 444±206 (± SD, maximum 738) days. Long-acting nitrates were administered in 312 patients (25%) after AMI. A comparison between groups based on clinical features revealed that patients on nitrates were more likely to be older, hypertensive, have high serum creatinine levels, previous MI and have been treated with a calcium-channel blocker. They were less likely to be current smokers and to have undergone emergency PCI. No differences were noted between the 2 groups with regard to sex, BMI, time from symptom onset to admission, peak CK, culprit location, Killip class, incidences of diabetes mellitus, hyperlipidemia, preinfarction angina pectoris, ST-segment elevation MI, Q-wave infarction, coronary multivessel involvement, and medications (aspirin, -blocker, angiotensin-converting enzyme inhibitor). group than in the non-nitrate control group. However, no significant differences were observed at 6 months, 1 year and 2 years after AMI. Cardiac events at 30 days and 60 days after AMI were more likely in the control group; however, there were no differences between the 2 groups after 90 days. Cardiovascular events were significantly lower only at 30 days after AMI.
Short-and Long-Term Adverse Events
Propensity Score Matching
Propensity score analysis with greedy matching was used to create matched pairs between the nitrate and control groups. In the present study, 172 cases were successfully matched in a 1:1 manner with 172 corresponding controls ( Table 3 ). There were no significant differences between the nitrate and control groups in all-cause mortality (Fig 1) , cardiac events (Fig 2) or cardiovascular events (Fig 3) 
Discussion
In the present study, we investigated the prognostic significance of long-term nitrate treatment after AMI in the coronary interventional era. Patients treated with nitrates showed good short-term prognosis compared with those who did not take nitrates, without adjusting for patient background. However, nitrate therapy did not improve adverse events after adjusting for all clinical characteristics.
Rapaport et al demonstrated that long-acting nitrate therapy reduced mortality rate during an average of 11 months after AMI 17 and the present results showed that nitrates improved 30-day, 60-day and 90-day mortality, 30-day and 60-day cardiac events, 30-day cardiovascular events according to crude comparisons. However, similar to the previous report, 17 the clinical background was markedly different between patients treated with and without nitrates. The prescription of calcium-channel blockers was more frequent in the nitrate group, possibly because of the limited number of patients who underwent PCI or had underlying serious conditions such as higher age, hypertension, high serum creatinine levels, previous MI, coronary multivessel involvement or complication of coronary spasm. Therefore the attending physicians may have considered there was a need for calcium-channel blockers in addition to nitrates. Accordingly, crude comparisons about future events after AMI should not be performed without taking these confounding factors into consideration. In this regard, overall randomized trials indicated that there was risk reduction of mortality with intravenous and oral nitrate treatments. 2, 18 Fitzgerald et al also reported that oral nitrates resulted in non-significant mortality reduction in patients with AMI followed up for 6 months. 19 These data suggest that nitrate treatment may be beneficial in patients with heart failure caused by moderate or large MI. On the other hand, Ishikawa et al 7 and Kanamasa et al 8 concluded from their prospective studies that long-term treatment with nitrates increased total mortality and cardiac events in patients after AMI during approximately 18-month follow-up period. However, the number of patients and their clinical backgrounds were quite different between patients treated with and without nitrates in those studies, and therefore the data randomization was insufficient.
There is a growing interest in the use of propensity score-based methods for estimating treatment effects in observational studies. The propensity score is defined as a subject's probability of treatment assignment conditional on measured covariates. 20, 21 To minimize the effect of selection bias on outcomes, we used the technique of propensity score matching for clinical characteristics and excluded distortion of confounding factors. Based on propensity score matching, nitrate treatment did not have any impact on post-AMI adverse events. The different results reported by previous groups on long-term nitrate treatment are mainly caused by an imbalance of patient background and whether trials were conducted in the prethrombolytic or thrombolytic era. The treatment policy for AMI has also changed over time. Currently in Japan, emergency PCI is aggressively performed in approximately 80% of patients with AMI and TIMI grade 3 flow of the culprit lesion is achieved in approximately 90%. [10] [11] [12] The trend in medical treatment for AMI has also varied widely over the past several decades. 22, 23 Nitrate tolerance may play an important role in increasing cardiac events. Nitrates can cause free radical production, endothelial dysfunction, and sympathetic activation, which reduce the generation and bioavailability of nitric oxide, and therefore nitrate therapy may have long-term detrimental effects. 24 On the other hand, long-term nitrate treatment does not increase vascular superoxide production despite impairment of the relaxant response. 25 The duration of nitrate treatment and follow-up period of the GISSI-3 5 and ISIS-4 6 trials were relatively short and large-scale randomized clinical trials concerning long-term nitrate treatment are required. At this stage, the clinical impact of nitrate tolerance is unclear and the effect of long-term nitrate therapy on clinical outcome is controversial. Importantly, Japanese have diffusely hyperreactive coronary arteries compared with Caucasians 26 and nitrates have been used for coronary artery disease, including coronary spasm, in many Japanese patients. In the Japanese -Blockers and Calcium antagonists Myocardial Infarction (JBCMI) study, the cardiovascular event rate was substantially higher in Western post-AMI patients than in Japanese receiving reperfusion therapy, which may contribute to the lower rates of morbidity and mortality. 27 In this regard, a common form of nitrate withdrawal (rebound) is observed in patients whose angina is intensified after discontinuation of nitrates, [28] [29] [30] so abrupt withdrawal after long-term administration of nitrates may be unsafe. A thorough examination is needed of the significance of post-AMI long-term nitrate therapy in the coronary interventional era. In the present study, nitrate therapy had little impact on long-term prognosis but did not result in poor clinical outcome in AMI patients. Therefore, nitrate therapy can be potentially effective in particular cases, such as patients with coronary spasm or heart failure caused by large MI. For secondary prevention, nitrates should be avoided in patients with healed MI who do not have additional myocardial ischemia and heart failure.
Study Limitations
This study was retrospective in nature. Patients were treated with nitrates soon after hospitalization and continued to receive them, but the amount of long-acting nitrates was not investigated in detail. However, our study included all patients with AMI entered in the 2003 database. All patients were followed after the onset of AMI, and thus the results of the present study should reflect the actual condition of patients with AMI in Japan. Prospective randomized clinical trials are warranted to determine the effects of long-term nitrate treatment for secondary prevention of AMI.
